[R01] ADAMTS13 in Human Health and Disease
Ente: National Heart Lung and Blood Institute
Scadenza: 2028-05-31
Importo max: 1.626.320 EUR
Paese: US
Descrizione
PROJECT SUMMARY
This application proposes to study thrombotic disorders linked by the common thread of ADAMTS13 deficiency.
The metalloprotease ADAMTS13 is responsible for cleaving ultra-large von Willebrand factor (VWF) multimers
into smaller units, thereby regulating the thrombogenicity of this important circulating coagulation factor. Immune
thrombotic thrombocytopenic purpura (iTTP) is a life-threatening autoimmune hematologic disorder
characterized by severe acquired ADAMTS13 deficiency (<10% activity, normal range: 50-150%) and diffuse
microvascular thrombosis, end-organ damage, and death if left untreated. Beyond iTTP, moderately low
ADAMTS13 (10-70% activity) has been hypothesized to contribute to common forms of macrovascular
thrombosis, including stroke and myocardial infarction. We plan to study both iTTP and less severe ADAMTS13
deficiency. We organized the Harvard TMA Research Collaborative (HTRC), one of the world’s largest single-
center registries for iTTP, to fuel innovative clinical and translational research of this understudied disease. Our
group has pioneered the application of robust statistical modeling approaches to key questions in iTTP as well
as the use of population-scale multidimensional datasets in hemostasis and thrombosis research. In Aim 1, we
will leverage the HTRC registry to identify upfront predictors of negative outcomes in ITTP, including relapse and
the composite of mortality, refractoriness, and need for critical care. Models developed in this Aim will facilitate
risk stratification of iTTP patients and help guide therapeutic decision-making. In Aim 2, common germline
genetic variants will be evaluated via the first genome-wide association and admixture mapping studies in iTTP
with a view to understanding the disproportionate disease risk borne by some populations. Project results will
provide avenues to develop novel screening, prevention, and intervention strategies for iTTP and serve as a
model for the study of other classical hematologic disorders. In Aim 3, we will analyze genomic and proteomic
data from nearly 800,000 individuals in the UK Biobank and NIH All of Us datasets to define the contribution of
moderate ADAMTS13 deficiency to widespread thrombotic conditions, including stroke, myocardial infarction,
peripheral artery disease, and venous thromboembolism. Our findings will have direct implications for clinical
practice due to the recent FDA approval of recombinant ADAMTS13 and the hypothesis that ADAMTS13
supplementation could potentially aid the many patients suffering from these forms of thrombosis.
Istituzione: BETH ISRAEL DEACONESS MEDICAL CENTER
PI: Pavan Bendapudi
Progetto: 1R01HL180838-01A1
Settori: National Heart Lung and Blood Institute
Vai al bando originale
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.